SOURCE: Zynex, Inc.

Zynex,  Inc.

October 16, 2014 08:00 ET

Zynex Hires Michael Frabotta as VP of Sales

LONE TREE, CO--(Marketwired - Oct 16, 2014) - Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, neurological diagnostics, and compound pharmacy, announced today the recent hire of Michael Frabotta as Vice President of Sales. Mr. Frabotta is responsible for Zynex Medical's sales organization, promoting electrotherapy and compound pharmacy products throughout the United States.

Mr. Frabotta has over 14 years of sales and management experience with RS Medical and ERMI, Inc. At RS Medical, a national competitor in the electrotherapy arena, he successfully served as a Director of Sales, National Director of Payor Contracting, Regional Manager, and Sales Representative. Mr. Frabotta received a Bachelor of Science in Nursing from the University of Pittsburgh where he specialized in Orthopedics.

Thomas Sandgaard, CEO of Zynex stated, "We are pleased to welcome Michael Frabotta as our new Vice President of Sales at Zynex. Mr. Frabotta is an expert in the electrotherapy field who has demonstrated success in both sales and sales management. We believe Michael will make a valuable contribution to the Company as we refocus on building our sales and marketing teams."

Robert Bird, Zynex's former VP of Sales and Marketing, has been named VP of Marketing and is now responsible for the Company's marketing and advertising including printed material, web-presence; pharmacy operations, product management, inside sales, and sales reporting.

About Zynex

Zynex, founded in 1996, operates under five primary business segments: Zynex Medical, NeuroDiagnostics, Monitoring Solutions, International, and Billing and Consulting. Zynex Medical engineers, manufactures, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex Medical's product lines are fully developed, FDA-cleared and commercially sold world-wide. Zynex Medical also operates a non-sterile compound pharmacy providing topical and transdermal pain creams. Zynex NeuroDiagnostics sells and distributes EMG, EEG, sleep pattern, auditory and nerve conductivity neurological devices. Zynex Monitoring Solutions, currently in the development stage, was established to develop and market medical devices for non-invasive cardiac monitoring. Zynex International is dedicated to supporting sales and marketing of Zynex products worldwide through a network of medical distributors. Zynex Billing and Consulting division provides medical billing and consulting service for offices and hospitals.

For additional information, please visit: www.ir-site.com/zynex.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our compound pharmacy and international expansion efforts, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2013.

Contact Information

  • Contact:
    Zynex, Inc.
    303-703-4906